It gives us pause to say for an average employer group out there if youre investing in this medication for your employees, dont expect to see a return in year one. According to Joseph Leach, M.D., Senior Vice President and Chief Medical Officer at Prime, We will need results of ongoing, multi-year studies to see if this treatment has downstream impacts on other health conditions, including cardiovascular events and diabetes development prevention, which are key benefits to weight loss management
When people eat and their blood sugar levels rise, GLP-1 receptor agonists stimulate the body to produce more insulin
Instead, aim the needle tip at the inside wall of the vial, near the top
Mounjaro, on the other hand, does what Semaglutide does, but also has been formulated to reduce the appetite